SUMMARY The efficacy of diltiazem in the treatment of Raynaud's phenomenon was assessed in a prospective double-blind randomised cross-over trial in 16 patients (7 progressive systemic sclerosis, 2 rheumatoid arthritis, 1 systemic lupus erythematosus, and 6 idiopathic Raynaud's phenomenon). Each patient received diltiazem 120 mg and placebo three times a day for two weeks. The attack frequency of Raynaud's phenomenon was measured by a diary count; its severity was assessed by means of a 10 cm visual analogue scale with 0 representing minimum and 10 representing maximum severity. Diltiazem significantly decreased the frequency and severity of Raynaud's phenomenon as compared with placebo. This improvement was striking in patients with idiopathic Raynaud's phenomenon but did not reach statistical significance in patients with associated systemic disease. We conclude that diltiazem is effective in the treatment of Raynaud's phenomenon, especially in patients with idiopathic vasospastic disease.
Raynaud's phenomenon may cause severe digital pain and functional disability, particularly in patients with underlying connective tissue disease. Trophic changes and fingertip ulcerations may develop in severe cases. The treatment of this condition is difficult. 1-3 We4 5 and others68 have shown that the calcium-channel blocking agent nifedipine is effective in the treatment of Raynaud's phenomenon. The calcium-channel blocker diltiazem causes vascular smooth-muscle relaxation and relief of coronary artery spasm.912 Diltiazem- induced vasodilation has been shown to result in an increase in peripheral blood flow.10 Diltiazem has been used to treat idiopathic Raynaud's phenomenon'3 and patients with vibration disease.14 We conducted a prospective, randomised, controlled, double-blind, cross-over trial to assess the effectiveness of diltiazem in the treatment of Raynaud's phenomenon in patients with underlying connective tissue disease and of idio-* Presented in part at the 56th Scientific Sessions of the American Heart Association, Anaheim, California, November 1983. Accepted for publication 5 During each period of the trial patients kept a record of their digital vasospastic attacks. Standardised diaries were provided for this purpose. The frequency of attacks was determined from the diary kept by the patient. The severity of Raynaud's phenomenon was assessed by means of a 10 cm visual analogue scale with 0 representing minimum and 10 representing maximum severity. At the end of each period of the trial patients were asked to evaluate subjectively the overall effectiveness of the study agents (marked or moderate improvement, no change, or worse).
The dependent variables measured in this study were frequency of vasospastic attacks, severity of Raynaud's phenomenon, and patient evaluation of the effectiveness of the study agent. The dependent variables to be measured were selected before the study was begun and were quantified before the drug code was broken. After completion of the analysis for all patients, subgroup analyses were performed. Patients were divided into two groups according to diagnosis: idiopathic Raynaud's phenomenon and Raynaud's phenomenon with systemic disease.
Statistical analysis. Differences in frequency and severity for the placebo and diltiazem periods Qf the study were analysed by means of Snedecor's F test. Differences in patient evaluation of the effectiveness of the study agent were analysed by means of Fisher's exact test.
Results
The results are shown in Table 1 . Diltiazem significantly reduced the frequency and severity of Raynaud's phenomenon in the whole group as compared with placebo. There was no order effect for either frequency or severity of Raynaud's phenomenon.
In the six patients with idiopathic Raynaud's phenomenon diltiazem significantly decreased the frequency and severity of attacks. In contrast, in the 10 patients with associated systemic disease (progressive systemic sclerosis, rheumatoid arthritis, and systemic lupus erythematosus), the reduction in frequency and severity of Raynaud's phenomenon did not reach statistical significance.
Marked or moderate improvement was reported by 9 of the 16 patients (4 idiopathic Raynaud's phenomenon and five with systemic disease) while they were taking diltiazem, and by 3 of them (2 idiopathic and 1 with systemic disease) while they were taking placebo (p=0-029, by Fisher's exact test). The differences in the therapeutic effect of diltiazem between the group with idiopathic Raynaud's phenomenon and the group with systemic disease could not be explained by differences in the initial frequency or severity of vasospastic attacks, nor by differences in the mean duration of Raynaud's phenomenon (13-8±11-0 and 12-2±10-3 years r-espectively), or the mean age (35-8±9.1 and 44i9± 11i9 years respectively).
The mean ambient temperature during the placebo and diltiazem periods of the study did not significantly differ.
At each visit inquiries were made about any side effects related to treatment. Side effects with diltiazem occurred in six patients: headache (2 patients), flushing (2 patients), dizziness (1 patient), nausea (2 patients), and ankle oedema (1 patient). Side effects with diltiazem were generally mild and no patient discontinued the study because of side effects. The only side effects reported with placebo were transient light-headedness (1 patient) and nausea (1 patient).
Discussion
During diltiazem treatment some of our patients had a decrease in the frequency of attacks and a moderate or marked improvement in symptoms of Raynaud's phenomenon. However, the response to therapy varied.
In all 16 patients and in patients with idiopathic Raynaud's phenomenon diltiazem significantly reduced the frequency and severity of Raynaud's phenomenon. However, in patients with associated systemic disease the frequency and severity of Raynaud's phenomenon during the placebo and diltiazem periods of the study did not significantly differ. There may be several explanations for this failure to detect a significant improvement in patients with associated connective tissue disease. The apparently 'negative' results in this group may be explained by the small number of patients in our study [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The differences may have been due to variation in the pathophysiology of Raynaud's phenomenon. 1 In our study side effects with diltiazem were mild. These findings accord with those of other studies suggesting that diltiazem is generally well tolerated.'( However, conduction disturbances have been reported. '0 Studies in animals have suggested a potential teratogenic effect.32 Although no similar experience has been reported in man to date, contraception should be recommended when diltiazem is prescribed for women of child-bearing age.
In conclusion, diltiazem significantly reduces the frequency and severity of Raynaud's phenomenon, especially in patients with idiopathic vasospastic disease. Further study is needed to determine the dose-response relation, the efficacy of long-term therapy, the predictors of clinical responsiveness, and mechanism of action of diltiazem in Raynaud's phenomenon. 
